Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 16
HOS-086250 · Präparat HOS-083284
Trazodone 50, single dose 200 q12h ↑ 2.4-fold ↑ 34%
An increase in the incidence in trazodone-related adverse reactions was noted when
co-administered with ritonavir dosed as an antiretroviral agent or as a
pharmacokinetic enhancer. If trazodone is co-administered with ritonavir, the
combination should be used with caution, initiating trazodone at the lowest dosage
and monitoring for clinical response and tolerability.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 17a1b1656a0f05d044cac2851bbe65b797a6e311337cc7c4e1ed9c41e4a683ad · Zeichen 26785–27471 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086439 · Präparat HOS-083284
Trazodone 50, single dose 200 q12h ↑ 2.4-fold ↑ 34%
An increase in the incidence in trazodone-related adverse reactions was noted when co-
administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic
enhancer. If trazodone is co-administered with ritonavir, the combination should be used
with caution, initiating trazodone at the lowest dosage and monitoring for clinical
response and tolerability.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage efb1aea0f4359822ff2b8aa593c55e0c8b279192756cce69f6aa78168d2e47e5 · Zeichen 27779–28478 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17
HOS-108895 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is
discontinued; therefore plasma
lamotrigine monitoring should be
conducted, particularly before and
during 2 weeks after starting or
stopping Kaletra, in order to see if
lamotrigine dose adjustment is
needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine
should be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg BID) similar increase in trazodone
Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are
increased due to CYP3A not recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra
should be avoided unless an
assessment of the benefit/risk to
patient justifies the use of
voriconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cc67e2cdf7b4bd67992a77fee82c028a01ca61b900711d375f1043368d2697bb · Zeichen 27086–30540 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53
HOS-109012 · Präparat HOS-093083
Due to induction of lamotrigine In patients starting or stopping
glucuronidation Kaletra while currently taking
maintenance dose of lamotrigine:
Valproate: ↓ lamotrigine dose may need to be
increased if Kaletra is added, or
decreased if Kaletra is discontinued;
therefore plasma lamotrigine
monitoring should be conducted,
particularly before and during 2
weeks after starting or stopping
Kaletra, in order to see if lamotrigine
dose adjustment is needed.
In patients currently taking Kaletra
and starting lamotrigine: no dose
adjustments to the recommended
dose escalation of lamotrigine should
be necessary.
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower dose
syncope were observed following of trazodone should be considered.
co-administration of trazodone
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg BID)
as contained in Kaletra should be
avoided unless an assessment of the
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) valproate (HOS-085955) ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage b7549f913c063162484a547a54d17aa41fc44fb9504b9f1472817c41a1f18572 · Zeichen 26672–29701 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89
HOS-109088 · Präparat HOS-093083
Antidepressants and Anxiolytics
Trazodone single dose Trazodone: It is unknown whether the
AUC: ↑ 2.4-fold combination of Kaletra causes a
(Ritonavir, 200 mg similar increase in trazodone
BID) Adverse events of nausea, exposure. The combination should
dizziness, hypotension and be used with caution and a lower
syncope were observed following dose of trazodone should be
co-administration of trazodone considered.
and ritonavir.
Antifungals
Ketoconazole and Ketoconazole, Itraconazole: High doses of ketoconazole and
Itraconazole Serum concentrations may be itraconazole (> 200 mg/day) are not
increased due to CYP3A recommended.
inhibition by lopinavir/ritonavir.
Voriconazole Voriconazole: Co-administration of voriconazole
Concentrations may be decreased. and low dose ritonavir (100 mg
BID) as contained in Kaletra should
be avoided unless an assessment of
the benefit/risk to patient justifies
the use of voriconazole.
Anti-gout agents:
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of colchicine-
related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9043d84be2324d7e08bc16eeeba0c8c1136fbb4075d51aeb08ee163e186d9cab · Zeichen 28361–32171 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 22
HOS-114853 · Präparat HOS-094169
Steady-state tipranavir/r
Digoxin Cmax ↓ 38%
Digoxin AUC ↔
Trazodone In a pharmacokinetic study The combination should be used
Interaction study performed in healthy volunteers, with caution and a lower dose of
performed only with concomitant use of low dose trazodone should be considered.
ritonavir ritonavir (200 mg twice daily)
with a single dose of trazodone
led to an increased plasma
concentration of trazodone (AUC
increased by 2.4 fold). Adverse
events of nausea, dizziness,
hypotension and syncope have
been observed following co-
administration of trazodone and
ritonavir in this study. However,
it is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in trazodone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) trazodone (HOS-086251) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 670ddbc82082775bbd9eb1b8fe463eabb7382dd9ec3661e309efc0cbfd787716 · Zeichen 59209–60356 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-116373 · Präparat HOS-094447
In contrast to these data with
PREZISTA/ritonavir,
PREZISTA/cobicistat may increase these
antidepressant plasma concentrations
(CYP2D6 and/or CYP3A inhibition).
Amitriptyline Clinical monitoring is
Desipramine Concomitant use of boosted PREZISTA recommended when
Imipramine and these antidepressants may increase co-administering boosted
Nortriptyline concentrations of the antidepressant. PREZISTA with these
Trazodone (CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
may be needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) trazodone (HOS-086251) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 4f4525e55eb9ba191fea6abaa7ec0b7cfb9e176370ce240a8d85cec068cb4990 · Zeichen 39141–40004 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-116522 · Präparat HOS-094447
Concomitant use of PREZISTA Clinical monitoring is
co-administered with low dose ritonavir recommended when
and these antidepressants may increase co-administering PREZISTA with
concentrations of the antidepressant. low dose ritonavir with these
(CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
Amitriptyline may be needed.
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted PREZISTA is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with PREZISTA
(induction of CYP450 enzymes) co-administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the
use of voriconazole.
Fluconazole Not studied. PREZISTA may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may increase daily dose of itraconazole should
darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 22f4e74ad4f26762902abfc0033ac15b80ded8bd1a23d2f6a966a8c972097288 · Zeichen 30842–32867 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 99
HOS-116612 · Präparat HOS-094447
In contrast to these data with
PREZISTA/ritonavir,
PREZISTA/cobicistat may increase these
antidepressant plasma concentrations
(CYP2D6 and/or CYP3A inhibition).
Amitriptyline Clinical monitoring is
Desipramine Concomitant use of boosted PREZISTA recommended when
Imipramine and these antidepressants may increase co-administering boosted
Nortriptyline concentrations of the antidepressant. PREZISTA with these
Trazodone (CYP2D6 and/or CYP3A inhibition) antidepressants and a dose
adjustment of the antidepressant
may be needed.
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and
considerations PREZISTA dose adjustment of metformin is
co-administered with cobicistat is recommended in patients who are
expected to increase metformin plasma taking PREZISTA co-administered
concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for PREZISTA
co-administered with ritonavir)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) trazodone (HOS-086251) ritonavir (HOS-084521) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 2c0dc2d9e3ddb0e0e92026d074dbaae3a3a70393cfdb47a97a09e403e78ecd72 · Zeichen 38675–40185 im Abschnitt
Wechselwirkungen · Zydelig
Zydelig 100 mg film-coated tablets Zydelig 150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-132102 · Präparat HOS-097192
7
Medicinal product Expected effect of Clinical recommendation upon
idelalisib on medicinal co-administration with idelalisib
product levels
ANTICOAGULANTS
Warfarin ↑ serum concentrations It is recommended that the
international normalised ratio (INR)
be monitored upon co-administration
and following ceasing treatment with
idelalisib.
ANTICONVULSANTS
Carbamazepine ↑ serum concentrations Anticonvulsant medicinal product
levels should be monitored.
ANTIDEPRESSANTS
Trazodone ↑ serum concentrations Careful dose titration of the
antidepressant and monitoring for
antidepressant response is
recommended.
ANTI-GOUT
Colchicine ↑ serum concentrations Dose reductions of colchicine may be
required. Idelalisib should not be
co-administered with colchicine to
patients with renal or hepatic
impairment.
ANTI-HYPERTENSIVES
Amlodipine, diltiazem, ↑ serum concentrations Clinical monitoring of therapeutic
felodipine, nifedipine, effect and adverse reactions is
nicardipine recommended.
ANTI-INFECTIVES
Antifungals
Ketoconazole, itraconazole, ↑ serum concentrations Clinical monitoring is recommended.
posaconazole, voriconazole
Antimycobacterials
Rifabutin ↑ serum concentrations Increased monitoring for rifabutin-
associated adverse reactions including
neutropenia and uveitis is
recommended.
HCV protease inhibitors
Boceprevir, telaprevir ↑ serum concentrations Clinical monitoring is recommended.
Macrolide antibiotics
Clarithromycin, telithromycin ↑ serum concentrations No dose adjustment of clarithromycin
is required for patients with normal
renal function or mild renal
impairment (creatinine clearance
[CrCl] 60-90 mL/min). Clinical
monitoring is recommended for
patients with CrCl < 90 mL/min. For
patients with CrCl < 60 mL/min,
alternative antibacterials should be
considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) felodipine (HOS-108908) carbamazepine (HOS-085618) rifabutin (HOS-086262) amlodipine (HOS-086287) creatinine (HOS-086273) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) trazodone (HOS-086251) boceprevir (HOS-090617) clarithromycin (HOS-084517) colchicine (HOS-086147) warfarin (HOS-085950) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-21T17:52:00Z · SHA-256 f55f90ba278a87ef1c8e7162344ed4bd66ac7180deaf4c8fda3eca5bbf8e87e5 · Passage 5f9a56fd2cd08a1553975154a7af1dc43198c97641aafb1794cd76642177c219 · Zeichen 4000–7499 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19–20
HOS-134030 · Präparat HOS-097520
19
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic areas levels. co-administration with Genvoya
Mean percent change in AUC,
Cmax, Cmin1
Tricyclic antidepressants (TCAs) Interaction not studied with any of Careful dose titration of the
Trazodone the components of Genvoya. antidepressant and monitoring for
Selective serotonin reuptake antidepressant response is
inhibitors (SSRIs) Concentrations of antidepressant recommended.
Escitalopram agents may be increased when
co-administered with cobicistat.
IMMUNOSUPPRESSANTS
Ciclosporin Interaction not studied with any of Therapeutic monitoring is
Sirolimus the components of Genvoya. recommended upon
Tacrolimus co-administration with Genvoya.
Concentrations of these
immunosuppressant agents may be
increased when administered with
cobicistat.
SEDATIVES/HYPNOTICS
Buspirone Interaction not studied with any of Co-administration of Genvoya and
Clorazepate the components of Genvoya. triazolam is contraindicated (see
Diazepam section 4.3). With other
Estazolam Triazolam is primarily metabolised sedatives/hypnotics, dose reduction
Flurazepam by CYP3A. Co-administration may be necessary and concentration
Lorazepam with Genvoya may result in monitoring is recommended.
Triazolam increased plasma concentrations of
Zolpidem this medicinal product, which is
associated with the potential for
serious or life-threatening adverse
reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) clorazepate (HOS-086164) lorazepam (HOS-085981) diazepam (HOS-085904) zolpidem (HOS-086327) serotonin (HOS-085477) trazodone (HOS-086251) tacrolimus (HOS-085202) buspirone (HOS-086325) sirolimus (HOS-085172) escitalopram (HOS-129417) triazolam (HOS-086168) flurazepam (HOS-086166)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 5942209e475c796ef61c4b0bb67f6fad6953705ca4043b5a69de6960506043d8 · Zeichen 46301–48689 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14–15
HOS-134494 · Präparat HOS-097580
14
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
ANTIDEPRESSANTS
Paroxetine paroxetine AUC ↓ 39% If antidepressants are co-
20 mg once daily paroxetine Cmin ↓ 37% administered with darunavir with
paroxetine Cmax ↓ 36% low dose ritonavir, the
recommended approach is a dose
#
darunavir AUC ↔
titration of the antidepressant based
#
darunavir Cmin ↔
on a clinical assessment of
#
darunavir Cmax ↔
antidepressant response. In addition,
Sertraline sertraline AUC ↓ 49% patients on a stable dose of these
50 mg once daily sertraline Cmin ↓ 49% antidepressants who start treatment
sertraline Cmax ↓ 44% with darunavir with low dose
#
darunavir AUC ↔ ritonavir should be monitored for
#
darunavir Cmin ↓ 6% antidepressant response.
#
darunavir Cmax ↔
Clinical monitoring is
recommended when co-
Concomitant use of darunavir co- administering darunavir with low
administered with low dose ritonavir dose ritonavir with these
and these antidepressants may increase antidepressants and a dose
concentrations of the antidepressant. adjustment of the antidepressant
(CYP2D6 and/or CYP3A inhibition) may be needed.
Amitriptyline
Desipramine
Imipramine
Nortriptyline
Trazodone
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may decrease Voriconazole should not be
plasma concentrations of voriconazole. combined with darunavir co-
(induction of CYP450 enzymes) administered with low dose
ritonavir unless an assessment of
the benefit/risk ratio justifies the use
of voriconazole.
Fluconazole Not studied. Darunavir may increase Caution is warranted and clinical
Isavuconazole antifungal plasma concentrations and monitoring is recommended. When
Itraconazole posaconazole, isavuconazole, co-administration is required the
Posaconazole itraconazole, or fluconazole may daily dose of itraconazole should
increase darunavir concentrations. not exceed 200 mg.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) domperidone (HOS-114656) voriconazole (HOS-084524) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) sertraline (HOS-086247) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 0e227ba8a8f0b79d0adea0b25305dcec4671959e568e634634a5edd206310734 · Zeichen 29798–33588 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 57
HOS-134621 · Präparat HOS-097580
Amitriptyline Concomitant use of boosted Clinical monitoring is recommended
Desipramine darunavir and these antidepressants when co-administering boosted
Imipramine may increase concentrations of the darunavir with these antidepressants
Nortriptyline antidepressant. and a dose adjustment of the
Trazodone (CYP2D6 and/or CYP3A antidepressant may be needed.
inhibition)
ANTI-DIABETICS
Metformin Not studied. Based on theoretical Careful patient monitoring and dose
considerations darunavir co- adjustment of metformin is
administered with cobicistat is recommended in patients who are
expected to increase metformin taking darunavir co-administered
plasma concentrations. with cobicistat.
(MATE1 inhibition) (not applicable for darunavir co-
administered with ritonavir)
ANTIEMETICS
Domperidone Not studied. Co-administration of domperidone
with boosted darunavir is
contraindicated.
ANTIFUNGALS
Voriconazole Not studied. Ritonavir may Voriconazole should not be
decrease plasma concentrations of combined with boosted darunavir
voriconazole. unless an assessment of the
(induction of CYP450 enzymes) benefit/risk ratio justifies the use of
voriconazole.
Concentrations of voriconazole may
increase or decrease when co-
administered with darunavir co-
administered with cobicistat.
(inhibition of CYP450 enzymes)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) cobicistat (HOS-088111) domperidone (HOS-114656) voriconazole (HOS-084524) trazodone (HOS-086251) ritonavir (HOS-084521) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 27799a8d8e538324cfbdb7d65793ead639dfa85c24213e1e87ce9b2c7b4b1622 · Zeichen 37685–39889 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-138484 · Präparat HOS-098200
Based on theoretical considerations
Amitriptyline DRV/COBI is expected to increase
Desipramine these anti-depressant plasma
Imipramine concentrations.
Nortriptyline (CYP2D6 and/or CYP3A
Trazodone inhibition)
ANTI-DIABETICS
Metformin Based on theoretical considerations Careful clinical monitoring and
DRV/COBI is expected to increase dose adjustment of metformin is
metformin plasma concentrations. recommended in patients who are
(MATE1 inhibition) taking Symtuza.
ANTIEMETICS
Domperidone Not studied. Co-administration of
domperidone with Symtuza is
contraindicated.
ANTIFUNGALS
Clotrimazole Based on theoretical considerations Caution is warranted and clinical
Fluconazole DRV/COBI is expected to increase monitoring is recommended.
Itraconazole these antifungal plasma When co-administration is
concentrations, and darunavir, required, the daily dose of
Isavuconazole cobicistat and/or tenofovir itraconazole should not exceed
Posaconazole alafenamide plasma concentrations 200 mg.
may be increased by the
antifungals.
(CYP3A and/or P-gp inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) isavuconazole (HOS-085186) nortriptyline (HOS-086245) amitriptyline (HOS-085911) desipramine (HOS-086249) imipramine (HOS-085907) clotrimazole (HOS-090574) domperidone (HOS-114656) itraconazole (HOS-084516) trazodone (HOS-086251) fluconazole (HOS-087945) posaconazole (HOS-085622) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 061584a4f2d3686461b02951b37d12cd2e74b66b2c1221794b17ed1d0cb7ecd1 · Zeichen 15577–17097 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.